NEWSROOM

NVAX

The Vaccine Investment Hypothesis, and What’s Next (AZN, JNJ, DYAI, BNTX)

The party is apparently “On” as far as the developed world’s sense of “reopening” is concerned. But the global truth is far removed from this celebration, as less than 20% of the world’s population have had access to a vaccine. The major vaccine producers struggle with the unit economics and production dynamics to solve this problem. Among countries with more than 1 million people, Mongolia is currently vaccinating faster than any other, administering a daily average of 1,790 doses per 100,000...

read more

Leading Vaccine Stocks Under the Microscope (PFE, NVAX, DYAI, MRNA)

The process of lining up the next wave of vaccines – Vax 2.0 – is likely already underway behind closed doors at major science institutes, throughout top research think-tanks, and at the home bases of the major vaccine-oriented pharma players. Vax 2.0 is no longer a theory. It’s already in the works. The Covid-19 variants are simply piling up too quickly, and too much of the world’s population remains unvaccinated. The world continues to be a petri dish of Darwinian trial and error for...

read more

Could Dyadic International (DYAI) be a Dark Horse Vaccine MVP

Dyadic International Inc (NASDAQ: DYAI) continues to take strong steps as a dark horse candidate to reshape the global vaccine landscape. The company posted results and an in-depth update late last week, and it’s worth taking a closer look. For a little background, DYAI has a new approach that could become a better way to deal with new variants and even possibly better able to drive cheap and efficient production capable of vaccinating the world comparted to those offered by Pfizer Inc (NYSE:...

read more

DYAI’s C1 Technology May be Key in the Race to Vaccine-Induced Herd Immunity

Dyadic International Inc (NASDAQ: DYAI) is in an interesting position, being one of the very few names in the anti-Covid space that offer a new path that isn’t simply a reproduction or tie-in to the big pharma game right now. DYAI has a new approach that isn’t new-age quote-unquote “science”, but a powerful new potential solution that holds the capacity to possibly become better able to deal with new variants and even possibly better able to drive cheap and efficient production capable of...

read more

New Approaches to Covid-19 Treatment Enter the Picture

The Covid-19 treatment response process includes a number of different major players, including Pfizer Inc (NYSE: PFE), BioNTech SE – ADR (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA), AstraZeneca plc (NASDAQ: AZN), Novavax Inc (NASDAQ: NVAX), Halberd Corp (OTC US: HALB), and Johnson & Johnson (NYSE: JNJ). The pandemic is under control. Or is it? In much of the developing world, this is far from the case. Only about 12% of people in the world have had access to vaccines. And new mutated...

read more

Spotlight: Progressive Care Inc. (OTC US: RXMD) Ramps Up Covid-19 Vaccinations (NASDAQ: AZN) (NASDAQ: MRNA) (NASDAQ: NVAX) (NYSE: PFE) (NYSE: CVS) (NASDAQ: WBA) (NYSE: RAD)

The vaccine is now a defining part of the world economy, with Evercore analysts predicting the first round of vaccinations (ie, those taking place this year before adjustments to new variants) will add up to about $140 billion in sales in the US. Stocks related to this theme make up a high interest group that includes Pfizer Inc (NYSE:PFE), Moderna Inc (NASDAQ:MRNA), AstraZeneca plc (NASDAQ:AZN), Novavax Inc (NASDAQ:NVAX), Walgreens Boots Alliance Inc (NASDAQ:WBA), CVS Health Corp (NYSE:CVS),...

read more

Is Dyadic International Inc. (NASDAQ: DYAI) the Key to the Next Wave of Vaccinations? (NASDAQ: AZN) (NASDAQ: MRNA) (NYSE: PFE) (NASDAQ: NVAX)

Bloomberg reported this morning that the world's wealthiest countries are vaccinating 25 times faster than the poorest. As of April 8, 40% of the shots administered have gone to people in 27 nations that represent just 11% of the global population. While the U.S. is on track to vaccinate 75% of its population in the next 90 days, almost half of the world’s nations have yet to reach 1%. The problem isn’t nationalist politics. The problem is vaccine production platforms that are unable to...

read more

Is Dyadic International Inc (NASDAQ: DYAI) the Key to Scaling Up Global Access to a Viable Covid-19 Vaccine? (NASDAQ: NVAX) (NASDAQ: MRNA) (NYSE: PFE) (NASDAQ: AZN)

While the pandemic feels “almost over” on many levels, experts believe the fundamental driver – a rapidly mutating coronavirus pathogen with uniquely formidable qualities – is likely, and unfortunately, here to stay as an endemic feature of the human microbiome going forward. In other words, Covid-19 is going to be with us for the long haul as a feature of life on earth for the human species possibly for centuries to come. That’s the bad news. But the good news is that, with big data, machine...

read more

Virus Plays in Focus as 2021 Gets in Gear (NASDAQ: NVAX) (OTC US: HALB) (NASDAQ: MRNA)

The re-opening narrative is dominating activity in the market and governs decisions being made in the business economy, and with good reason. Perhaps never before has so much value been tied to such a singular and distinct dynamic. That naturally defines the value proposition of companies working to provide those solutions. With vaccines a powerful piece of that equation, this drives eyeballs to the vaccine developers. But vaccines aren’t the only piece of the puzzle. With that in mind, we...

read more

Categories

Mcap MediaWire - Costumer Service

Translate »